172 related articles for article (PubMed ID: 22949131)
1. Dapsone 5% gel: a new option in topical therapy for acne.
Tan J
Skin Therapy Lett; 2012 Sep; 17(8):1-3. PubMed ID: 22949131
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the anti-inflammatory effects of topical dapsone for management of acne.
Kircik LH
J Drugs Dermatol; 2010 Jun; 9(6):667-71. PubMed ID: 20645528
[TBL] [Abstract][Full Text] [Related]
3. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
Stotland M; Shalita AR; Kissling RF
Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
[TBL] [Abstract][Full Text] [Related]
4. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne.
Scheinfeld N
Curr Opin Investig Drugs; 2009 May; 10(5):474-81. PubMed ID: 19431080
[TBL] [Abstract][Full Text] [Related]
5. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
Lucky AW; Maloney JM; Roberts J; Taylor S; Jones T; Ling M; Garrett S;
J Drugs Dermatol; 2007 Oct; 6(10):981-7. PubMed ID: 17966175
[TBL] [Abstract][Full Text] [Related]
6. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of dapsone gel 5% in the treatment of acne vulgaris.
Pickert A; Raimer S
Expert Opin Pharmacother; 2009 Jun; 10(9):1515-21. PubMed ID: 19505219
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
Tanghetti E; Harper JC; Oefelein MG
J Drugs Dermatol; 2012 Dec; 11(12):1417-21. PubMed ID: 23377510
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
Stein Gold LF; Jarratt MT; Bucko AD; Grekin SK; Berlin JM; Bukhalo M; Weiss JS; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
J Drugs Dermatol; 2016 May; 15(5):553-61. PubMed ID: 27168264
[TBL] [Abstract][Full Text] [Related]
11. Dapsone 7.5% Gel: A Review in Acne Vulgaris.
Al-Salama ZT; Deeks ED
Am J Clin Dermatol; 2017 Feb; 18(1):139-145. PubMed ID: 28005194
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
Taylor SC; Cook-Bolden FE; McMichael A; Downie JB; Rodriguez DA; Alexis AF; Callender VD; Alvandi N
J Drugs Dermatol; 2018 Feb; 17(2):160-167. PubMed ID: 29462223
[TBL] [Abstract][Full Text] [Related]
14. Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment.
Kircik LH
J Drugs Dermatol; 2016 Feb; 15(2):191-5. PubMed ID: 26885787
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
Raimer S; Maloney JM; Bourcier M; Wilson D; Papp K; Siegfried E; Garrett S;
Cutis; 2008 Feb; 81(2):171-8. PubMed ID: 18441772
[TBL] [Abstract][Full Text] [Related]
16. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?
Webster GF
J Drugs Dermatol; 2010 May; 9(5):532-6. PubMed ID: 20480797
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience With Once-Daily Dapsone Gel, 7.5% Monotherapy in Patients With Acne Vulgaris.
Stockton TC; Tanghetti EA; Lain E; Zeichner JA; Alvandi N
J Drugs Dermatol; 2018 Jun; 17(6):602-608. PubMed ID: 29879247
[TBL] [Abstract][Full Text] [Related]
18. Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
Jarratt MT; Jones TM; Chang-Lin JE; Tong W; Berk DR; Lin V; Kaoukhov A
J Drugs Dermatol; 2016 Oct; 15(10):1250-1259. PubMed ID: 27741344
[TBL] [Abstract][Full Text] [Related]
19. Newer topical therapies for the treatment of acne vulgaris.
Del Rosso JQ
Cutis; 2007 Nov; 80(5):400-10. PubMed ID: 18189027
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color.
Alexis AF; Burgess C; Callender VD; Herzog JL; Roberts WE; Schweiger ES; Stockton TC; Gallagher CJ
J Drugs Dermatol; 2016 Feb; 15(2):197-204. PubMed ID: 26885788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
